Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ingrid B. Joseph"'
Autor:
Jerod L. Ptacin, Lina Ma, Carolina E. Caffaro, Nicole V. Acuff, Kristine Germar, Peter Severy, Yanyan Qu, Jose-Luis Vela, Xinming Cai, Kristine M. San Jose, Hans R. Aerni, David B. Chen, Ean Esche, Taylor K. Ismaili, Rob Herman, Yelena Pavlova, Michael J. Pena, Jasmine Nguyen, Lilia K. Koriazova, Laura K. Shawver, Ingrid B. Joseph, Jill Mooney, Mark Peakman, Marcos E. Milla
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-16 (2024)
Abstract Background Natural cytokines are poorly suited as therapeutics for systemic administration due to suboptimal pharmacological and pharmacokinetic (PK) properties. Recombinant human interleukin-2 (rhIL-2) has shown promise for treatment of aut
Externí odkaz:
https://doaj.org/article/224e433676bd420da232e1c317680a2d
Autor:
Jerod L. Ptacin, Carolina E. Caffaro, Lina Ma, Kristine M. San Jose Gall, Hans R. Aerni, Nicole V. Acuff, Rob W. Herman, Yelena Pavlova, Michael J. Pena, David B. Chen, Lilia K. Koriazova, Laura K. Shawver, Ingrid B. Joseph, Marcos E. Milla
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
The use of synthetic organisms could provide opportunities for discovery and advanced manufacturing of medical drugs. Here the authors use a semi-synthetic organism with an expanded genetic code to generate site-specific chemical modifications in hum
Externí odkaz:
https://doaj.org/article/1eeb5f339edc4637a3c9f0f0c17dcf95
Autor:
Kristine M San Jose Gall, Marcos Milla, Caffaro Carolina E, Michael J. Pena, Laura K. Shawver, Ingrid B. Joseph, Ptacin Jerod, David B. Chen, Nicole V Acuff, Lina Ma, Lilia K. Koriazova, Yelena Pavlova, Hans R. Aerni, Rob W Herman
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature Communications
Nature Communications
The implementation of applied engineering principles to create synthetic biological systems promises to revolutionize medicine, but application of fundamentally redesigned organisms has thus far not impacted practical drug development. Here we utiliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5732ddaedc3b48d14ed6d810fb3614aa
https://doaj.org/article/1eeb5f339edc4637a3c9f0f0c17dcf95
https://doaj.org/article/1eeb5f339edc4637a3c9f0f0c17dcf95
Autor:
R.W. Herman, Lilia K. Koriazova, David B. Chen, Ptacin Jerod, L.K. Shawver, K.M. San Jose, T.K. Ismaili, Lina Ma, Marcos Milla, Michael J. Pena, Caffaro Carolina E, J. Nguyen, Yelena Pavlova, N. Singh, Ingrid B. Joseph, Hans R. Aerni, S. Li
Publikováno v:
Annals of Oncology. 30:v501
Background THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR-707 has near-native binding affinity for the βγ chain of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39915bf6c2a4e1fd3fb48ba423f47f30
https://doi.org/10.1093/annonc/mdz253.051
https://doi.org/10.1093/annonc/mdz253.051
Autor:
Lilia K. Koriazova, Hans R. Aerni, Michael J. Pena, Jasmine Nguyen, Ken Bragstad, Shukuan Li, Marcos Milla, Yelena Pavlova, Caffaro Carolina E, Ptacin Jerod, Robert W. Herman, Kristine M. San Jose, David B. Chen, Lina Ma, Ingrid B. Joseph, Laura K. Shawver
Publikováno v:
Cancer Research. 79:3258-3258
Aldesleukin is a recombinant form of IL-2 approved for metastatic melanoma and renal cell carcinoma that induced complete, durable remissions in certain patients. Yet, its use is infrequent because of vascular leak syndrome (VLS), a severe dose-limit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f4bcec31c14b1593f1218cdd2ea39f0
https://doi.org/10.1158/1538-7445.am2019-3258
https://doi.org/10.1158/1538-7445.am2019-3258
Autor:
Lina Ma, Ptacin Jerod, Marcos Milla, Lilia K. Koriazova, Hans R. Aerni, Laura K. Shawver, Caffaro Carolina E, Ingrid B. Joseph
Publikováno v:
Journal of Clinical Oncology. 37:2603-2603
2603 Background: Recombinant interleukin-2 (rIL-2; aldesleukin) is an approved immunotherapy in melanoma and renal cell carcinoma based on complete durable remissions. The anti-neoplastic properties of IL-2 are mediated by interactions with the beta-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d94c27896c2ca30356d3faf47e6b4a65
https://doi.org/10.1200/jco.2019.37.15_suppl.2603
https://doi.org/10.1200/jco.2019.37.15_suppl.2603